Answers are grounded in this paper and cite their sources.
Discovery of GSK251 shows improved potency and selectivity in inhibiting PI3Kδ, indicating potential for further development.
Optimization of a previously reported lead series of PI3Kδ inhibitors with a novel binding mode led to the identification of a clinical candidate compound 31 (GSK251). Removal of an embedded Ames-positive heteroaromatic amine by reversing a sulfonamide followed by locating an interaction with Trp760 led to a highly selective compound 9. Further optimization to avoid glutathione trapping, to enhance potency and selectivity, and to optimize an oral pharmacokinetic profile led to the discovery of compound 31 (GSK215) that had a low predicted daily dose (45 mg, b.i.d) and a rat toxicity profile suitable for further development.
No takes yet. Share an insight, caveat, or question.
Down et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: